NCT02599194 - 18F-FSPG PET/CT for Cancer Patients on Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 14, 2016

Study Completion Date

December 14, 2016

Conditions

B-Cell NeoplasmEstrogen Receptor NegativeHER2/Neu NegativeMetastatic Renal Cell CancerProgesterone Receptor NegativeStage III MesotheliomaStage III Renal Cell CancerStage IIIA Breast CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IIIC Breast CancerStage IV Breast CancerStage IV MesotheliomaStage IV Non-Small Cell Lung CancerStage IV Renal Cell CancerTriple-Negative Breast Carcinoma

Interventions

DRUG

18F-FSPG

Administered intravenously (IV)

DRUG

18F-FDG

Administered intravenously (IV)

Trial Locations (1)

94304

Stanford University Medical Center, Stanford

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Andrei Iagaru

OTHER